Drug Trials Life Science Research 
XTalks
JULY 29, 2021
Just as clinical researchers in other therapeutic areas have renewed their commitment to improving participant diversity in clinical trials, so too have those working in Alzheimer’s research. Fortunately, there are a number of researchers working on this issue. Similarly, older Latino and Hispanic individuals are 1.5
pharmaphorum
DECEMBER 1, 2022
To ease this burden, the life sciences industry has been searching for ways to make clinical trials more accessible for patients and to drive participation numbers, increase participant diversity, and improve overall patient experience. Imagine, clinical research as an accessible care option to anyone. Keep it simple.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Velocity Clinical Research
OCTOBER 21, 2024
At the beginning of September, Velocity Clinical Research topped Business North Carolina ’s 2024 Fast 40 list. For a clinical trials organization to achieve this level of scale is notable. This is vital if we’re to ensure that drug trials are inclusive and deliver results that are representative of the entire population.
XTalks
MAY 16, 2023
RELATED: New Report Highlights Major Barriers to IPF Disease Management Clinical trials for pulmonary fibrosis play a crucial role in advancing our understanding of the disease and developing new treatment options. They aim to improve patient outcomes, slow disease progression and enhance quality of life.
XTalks
APRIL 26, 2021
After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.
XTalks
SEPTEMBER 11, 2020
Expanding minority Americans’ access to care and clinical trials isn’t just the right thing to do. Clinical Trials Don’t Reflect Demographics. Disease doesn’t discriminate, and researchers understand different populations react differently to drugs. Why, then, are clinical trials so stubbornly homogeneous?
Advarra
AUGUST 16, 2022
Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. Other FDA Orphan Disease Focus Areas.
Expert insights. Personalized for you.
98 
Let's personalize your content